BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zhou JM, Xiong HF, Chen XP, Zhang ZW, Zhu LP, Wu B. Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study. World J Gastrointest Oncol 2023; 15(4): 689-699 [PMID: 37123056 DOI: 10.4251/wjgo.v15.i4.689]
URL: https://www.wjgnet.com/1948-5204/full/v15/i4/689.htm
Number Citing Articles
1
Taito Fukushima, Satoshi Kobayashi, Makoto Ueno. The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitorsJapanese Journal of Clinical Oncology 2024; 54(9): 949 doi: 10.1093/jjco/hyae067
2
Miki Kawano, Yoshihiko Yano, Atsushi Yamamoto, Eiichiro Yasutomi, Yuta Inoue, Jun Kitadai, Ryutaro Yoshida, Takanori Matsuura, Yuuki Shiomi, Yoshihide Ueda, Yuzo Kodama. Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver BiopsyDiagnostics 2024; 14(8): 815 doi: 10.3390/diagnostics14080815
3
Xiu Chen, Liqiu Kou, Xiaolu Xie, Song Su, Jun Li, Yaling Li. Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinomaImmunology 2024; 172(1): 21 doi: 10.1111/imm.13751